NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds

B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutr

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL)

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.52) per share which missed the an

NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics NASDAQ: CADL is advancing two off-the-shelf viral immunotherapy candidates desig

Candel Therapeutics, Inc. remains a Buy as its lead asset, CAN-2409, advances toward FDA submission

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy

NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncolog

NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical

Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with

NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free surviv

NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

NEEDHAM, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics NASDAQ: CADL Chief Executive Officer Dr. Paul Peter Tak said the company remains

The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the

Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free su

Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagen

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.14) per share which beat the anal

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical

Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how nar

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and ra

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clini

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lo

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.54) per share which missed the an

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical

(Editor's note: The future prices of benchmark tracking ETFs, the lede, and the headline were up

Candel Therapeutics stock down on public offering pricing, intends to use proceeds for cancer therap

Stephens & Co. analyst Sudan Loganathan reiterates Candel Therapeutics (NASDAQ:CADL) with a O

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical

Stephens & Co. analyst Sudan Loganathan initiates coverage on Candel Therapeutics (NASDAQ:CAD

Trinity Capital Inc. announced a financing agreement with Bobbie, an organic infant nutrition compan

LifeSci Capital initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Outperform rating a

$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company